H
HBANZ
NOW TRADING POST CALL DATE
About this security
HBANZ is a 5.5% non-cumulative perpetual preferred stock issued by Huntington Bancshares Incorporated Depositary Shares Each Representing a 11000th Interest in a Share of 5.50 Series L NonCumulative Perpetual Preferred Stock, a National Commercial Banks issuer. $25 liquidation preference, current yield 7.40%, callable from 2024-11-20.
Key Stats ✓ terms from SEC filing — verify via link below ✓ verified against SEC filing
vs. National Commercial Banks category (11 issues): yield 7.40% vs avg 8.01% · discount -25.7% vs avg -7.2%
Quote
| HBANZ (preferred) | |
|---|---|
| Last | $18.58 |
| Change | — |
| Open | $18.56 |
| High / Low | $18.64 / $18.40 |
| Prev Close | — |
| Volume | 13,105 |
| 52-Week High / Low | $22.23 / $18.38 |
52-week range based on available history. Shares outstanding / market cap require a fundamentals feed (not in current data plan).
Price
Dividend History
| Ex-Date | Amount / Share |
|---|---|
| 2026-08-05 | $0.343750 |
| 2026-04-30 | $0.343750 |
Performance — $10K Calculator
Dividends reinvested (DRIP) at the close on each ex-date. Full performance page →
Prospectus (SEC 424B5)
News — Huntington Bancshares Incorporated Depositary Shares Each Representing a 11000th Interest in a Share of 5.50 Series L NonCumulative Perpetual Preferred Stock
- Follow The Flow of the Marijuana Money: Former DEA Chief Questions Why DEA Ignored Rules — finance.yahoo.com · Jun 20, 2026
- Hot Picks: Verizon, Huntington, Cactus offer dividend growth opportunities — bnnbloomberg.ca · Jun 19, 2026
- QURE Soars as FDA Backs AMT-130 Data for Accelerated Approval — finance.yahoo.com · Jun 19, 2026
- uniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy — finance.yahoo.com · Jun 19, 2026
- Marzetti And 2 Other Leading Dividend Stocks — simplywall.st · Jun 19, 2026
- Have Insiders Sold Huntington Bancshares Shares Recently? — simplywall.st · Jun 19, 2026
- uniQure Soars After FDA's U-Turn Opens Accelerated Approval Pathway for Huntington's Therapy — benzinga.com · Jun 18, 2026
- How biotech executives are confronting the funding and regulatory shifts — finance.yahoo.com · Jun 18, 2026
Issuer news via Tiingo, tagged to HBAN.